Enfermedad pulmonar intersticial fibrosante progresiva (EPI-FP)

 

Effect of nintedanib on decline in forced vital capacity (FVC) in patients with progressive fibrosing interstitial lung diseases (ILDs) by GAP stage

Ryerson CJ et al.
 

Acceder

Effects of nintedanib in patients with progressive fibrosing interstitial lung diseases (ILDs) by composite physiologic index (CPI)

Nambiar AM et al.
 

Acceder

Effect of nintedanib on decline in forced vital capacity (FVC) in patients with progressive fibrosing interstitial lung diseases (ILDs) by time since diagnosis

Strek ME et al.
 

Acceder

 

 

Effects of nintedanib in patients with progressive fibrosing interstitial lung diseases (ILDs) taking anti-acid therapy

Kreuter M et al.


 

Acceder

Decline in forced vital capacity as a surrogate for mortality in patients with fibrosing interstitial lung diseases

Maher TM et al.


 

Acceder

Lung function decline and hospitalization among patients with non-IPF fibrosing interstitial lung disease as observed in a large real-world electronic health record database

Singer D et al.
 

Acceder

 

 

Incremental healthcare resource utilization and cost burden associated with non-IPF chronic fibrosing interstitial lung disease (ILD) with a progressive phenotype

Singer D et al.
 

Acceder